209982-91-2

Basic information

• Product Name: Benzeneacetic acid, 3,5-difluoro-α-hydroxy-, (αS)-
• Synonyms: Benzeneacetic acid, 3,5-difluoro-α-hydroxy-, (αS)-;(S)-2-(3,5-difluorophenyl)-2-hydroxyacetic acid
• CAS NO: 209982-91-2
• Molecular Formula: C₈H₆F₂O₃
• Molecular Weight: 188.1282464
• Mol File: 209982-91-2.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzeneacetic acid, 3,5-difluoro-α-hydroxy-, (αS)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzeneacetic acid, 3,5-difluoro-α-hydroxy-, (αS)-(209982-91-2)
• EPA Substance Registry System: Benzeneacetic acid, 3,5-difluoro-α-hydroxy-, (αS)-(209982-91-2)

Safety Data

• Hazardous Substances Data: 209982-91-2(Hazardous Substances Data)

Upstream product

• 209982-92-3 Methyl S-(+/-)-3,5-difluoromandelate 
• 132741-31-2 S-(+)-3.5-Difluoromandelic Acid 

Downstream Products

• 528610-90-4 (S)-2-{(S)-2-[(S)-2-(3,5-Difluoro-phenyl)-2-hydroxy-acetylamino]-propionylamino}-hexanoic acid methyl ester 
• 935525-13-6 C₂₁H₂₀F₂N₄O₄ 
• 935525-13-6 BMS-433796 
• 1027299-17-7 5-{N'-[(S)-3,5-difluoromandelyl]-L-alaninyl}amino-7-cyclopropylmethyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one 
• 1026296-79-6 5-{N'-[(S)-3,5-difluoromandelyl]-L-valinyl}amino-7-cyclopropylmethyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one 
• 1026859-19-7 5-{N'-[(S)-3,5-difluoromandelyl]-L-valinyl}amino-10-fluoro-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one 
• 1027225-59-7 5-{N'-[(S)-3,5-difluoromandelyl]-L-valinyl}amino-9-fluoro-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one 
• 209995-97-1 3-[N'-(3,5-difluorophenyl-α-hydroxyacetyl)-L-valinyl]-amino-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepin-2-one 

Relevant articles and documents

Enzymatic Resolution by a d-Lactate Oxidase Catalyzed Reaction for (S)-2-Hydroxycarboxylic Acids

Oxidase-catalyzed kinetic resolution is important for the production of enantiopure 2-hydroxycarboxylic acids (2-HAs), which are versatile building blocks for the synthesis of many significant compounds. However, in contrast to that of (R)-2-HAs, the production of (S)-2-HA is challenging because of the lack of related oxidases. Herein, suitable enzymes were screened systematically through the analysis of numerous putative d-lactate oxidase sequences and identification of several required properties. Finally, a d-lactate oxidase from Gluconobacter oxydans 621H with advantageous characteristics, such as good solubility, broad substrate spectrum, and high stereoselectivity, was selected to resolve 2-HAs into (S)-2-HAs. A variety of (S)-2-HAs was produced successfully using this d-lactate oxidase with excellent enantiomeric excess values (>99 %). The presented screening criteria and approach for target biocatalysis suggested a guideline for the production of optically active chemicals such as (S)-2-HAs.

Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds

Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds

Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.